Cue Biopharma, Inc. (CUE) - Rasio utang jangka dawa marang ekuitas

Production optimization via a CDMO network minimizes downtime risks for Cue Biopharma, Inc. (CUE). The long-term debt-to-equity ratio trend demonstrates current leverage, with the metric standing at 3.27. While the high authority of the Immuno-STAT platform sustains oncologist confidence, geopolitical tensions and sanctions hinder international trials and biomaterial shipments, creating barriers to the company's growth.

The long-term debt-to-equity ratio measures the proportion of liabilities with a maturity exceeding one year within the equity structure. An increase in this metric signals rising financial leverage and a greater dependence on borrowed funds. By analyzing the current long-term debt-to-equity ratio, an investor assesses the stability of the company's balance sheet. A low level of borrowing is critical for Cue Biopharma, Inc. (CUE) when scaling joint developments in the field of immunotherapy.